<DOC>
	<DOCNO>NCT01047072</DOCNO>
	<brief_summary>The purpose study see well reduce intensity conditioning follow stem cell transplant donor ( allogeneic ) work treat patient severe systemic sclerosis . In allogeneic stem cell transplant procedure , stem cell take healthy donor transplant patient . Stem cell donate family member unrelated donor complete tissue type match .</brief_summary>
	<brief_title>Low-Dose Conditioning Followed Donor Stem Cell Transplant Treating Patients With Severe Systemic Sclerosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate overall effect allogeneic hematopoietic cell transplantation ( HCT ) systemic sclerosis ( SSc ) . II . To assess potential efficacy , term event-free survival ( EFS ) 2 ( part 1 ) 5 ( part 2 ) year , allogeneic HCT treatment patient severe SSc . SECONDARY OBJECTIVES : I . To evaluate rate complication allogeneic HCT nonmyeloablative conditioning include incidence graft rejection , regimen-related toxicity , severe acute chronic graft-vs-host disease ( GVHD ) , infectious complication , treatment-related mortality ( TRM ) , overall survival . II . To evaluate treatment effect disease activation/progression , indicate measure cardiac , pulmonary , gastrointestinal renal function , well skin thickness , overall functional assessment ( SHAQ ) , use concomitant disease-modifying antirheumatic drug ( DMARDs ) , occurrence myositis . III . To evaluate disease response nonmyeloablative conditioning allogeneic HCT immunomodulatory therapy , assess skin disease modify Rodnan Skin Score ( mRSS ) , pulmonary function measure diffuse capacity lung carbon monoxide ( DLCO ) force vital capacity ( FVC ) , Modified Scleroderma Health Assessment Questionnaire ( SHAQ ) , Quality Life use Short Form 36 ( SF36 ) . IV . To evaluate , mechanistic study , effect allogeneic HCT dermal fibrosis vasculopathy . V. To evaluate late complication allogeneic HCT nonmyeloablative conditioning include incidence prevalence chronic GVHD time discontinue immunosuppression , infectious complication , TRM overall survival . VI . To evaluate treatment effect disease activation/ progression , indicate measure cardiac , pulmonary , gastrointestinal renal function , well skin thickness , overall functional assessment ( SHAQ ) , use concomitant DMARDs , occurrence myositis . VII . To evaluate disease response nonmyeloablative conditioning allogeneic HCT immunomodulatory therapy , assess skin disease modify Rodnan Skin Score ( mRSS ) , pulmonary function measure DLCO FVC , Modified Scleroderma Health Assessment Questionnaire ( SHAQ ) , Quality Life use Short Form 36 ( SF36 ) . OUTLINE : Patients assign 1 2 treatment arm receive nonmyeloablative conditioning follow allogeneic peripheral blood stem cell transplantation . Treatment arm continue absence disease progression unacceptable toxicity . ARM I ( transplant ) : Patients receive fludarabine intravenously ( IV ) day -4 -2 . Patients undergo total-body irradiation day 0 . Patients undergo peripheral blood stem cell transplantation day 0 . Patients receive GVHD prophylaxis comprise tacrolimus orally ( PO ) twice daily day -3 180 taper mycophenolate mofetil PO three time daily day 0-28 twice daily day 180 taper . ARM II ( nontransplant ) : Patients receive immunosuppressive therapy base history . The 3 option may receive include 1 . ) mycophenolate mofetil PO twice daily 16 month , 2 . ) Rituximab IV day 1 15 repeat 6 month , 3 . ) Cyclophosphamide IV 28-32 day interval orally daily 16 month . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Patients severe SSc define American College Rheumatology highrisk fatal outcome base following prognostic factor group 15 : Group 1 : Patients 1 ) a. b. ; 2 ) least one c. , d. e : a. Diffuse cutaneous scleroderma skin score &gt; = 16 ( modify Rodnan skin scale ) b . Duration systemic sclerosis = &lt; 5 year onset first nonRaynaud 's symptom c. Presence interstitial lung disease FVC DLCOcorr = &lt; 70 % predict evidence alveolitis ( abnormal bronchoalveolar lavage [ BAL ] high resolution chest compute tomography [ CT ] scan ) d. Left heart failure leave ventricular ejection Fraction ( LVEF ) &lt; 50 % pericardial effusion ( mildmoderate ) 2nd 3rd AtrialVentricular ( AV ) block ; Myocardial disease secondary SSc must exclude cardiologist e. History SScrelated renal disease active time screening ; History scleroderma hypertensive renal crisis include criterion Group 2 : Patients progressive pulmonary disease primary indication transplant define decrease FVC DLCO 15 percent great previous 12month period . In addition , patient may either less skin involvement group 1 ( mRSS &lt; 16 ) history diffuse cutaneous disease FVC DLCOcorr &lt; 70 % FVC DLCOcorr &gt; = 70 % diffuse cutaneous disease ( mRSS &gt; 16 ) screening study ; Patients must also evidence alveolitis define abnormal chest CT BAL Group 3 : Have progressive active SSc prior autologous HCT base presence progressive pulmonary disease ; This define decrease FVC since prior autologous transplant 10 percent great , DLCO since prior autologous transplant 15 percent great addition evidence alveolitis define chest CT change BAL ; If patient prior autologous HCT SCOT clinical trial , must fail base defined study endpoint approve protocol principal investigator ( PI ) Group 4 : Patients meet group 1 inclusion criterion FVC DLCO &lt; 70 % plus adverse event cyclophosphamide prevent use ( i.e. , hemorrhagic cystitis , leucopenia WBC , 2000 ANC &lt; 1000 platelet count &lt; 100,000 adverse event ) Group 5 : Diffuse scleroderma disease duration = &lt; 2 year since development first sign skin thicken plus modified Rodnan skin score &gt; = 25 plus ESR &gt; 25 mm/1st hour and/or Hb &lt; 11 g/dL explain cause active scleroderma . 2 . Unless patient DLCOcorr le 45 % , patient must fail either oral intravenous cyclophosphamide regimen define : IV cyclophosphamide administration &gt; 6 month total cumulative IV dose 6 g/m^2 , oral cyclophosphamide administration &gt; 6 month regardless dose , combination oral IV cyclophosphamide &gt; 6 month independent dose 3 . Patient must sibling ) HLAidentical b ) could serve donor peripheral blood stem cell graft place transplant arm unrelated donor match HLAA , B , C , DRB1 DQB1 . Patients without HLAidentical sibling HLAmatched unrelated donor meet criterion place nontransplant arm DONOR : The donor must HLAidentical sibling patient HLAmatched unrelated donor . If donor reach age assent , must complete local institutional review board ( IRB ) assent process . Donor must consent GCSF administration leukapheresis HSC collection . Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) . Age 1275 year ; Pediatric donor must &gt; 50 kg body weight . Eligible NIHsponsored randomize clinical trial ( SCOT ) Fertile men woman unwilling use contraceptive technique 12 month immunosuppression discontinue follow transplantation Evidence ongoing active infection Pregnancy Subjects pulmonary , cardiac , hepatic , renal impairment would limit ability receive therapy compromise survival . This include restricted , subject follow : Severe pulmonary dysfunction define : 1 . A hemoglobin correct DLCOcorr &lt; 30 % FVC &lt; 40 % predict ; 2 . O2 saturation &lt; 92 % rest without supplemental oxygen ; 3 . PO2 &lt; 70 mmHg pCO2 &gt; 50 mmHg without supplemental oxygen Significant uncontrolled pulmonary hypertension define : 1 . Pulmonary artery peak systolic pressure &gt; 45 mmHg echocardiogram mean pulmonary artery pressure right heart catheterization exceed 32 mmHg rest 42 mm Hg exercise ; 2 . New York Heart Association ( NYHA ) /World Health Organization ( WHO ) classification pulmonary hypertension , Class III IV Cardiac : Uncontrolled clinically significant arrhythmia ; clinical evidence significant cardiac disease ( NYHA Class III IV ) ; LVEF &lt; 40 % echocardiogram Significant renal pathology , define : 1 . Estimated CrCl &lt; 60 mL/min ( use CockcroftGault formula base actual body weight ) serum creatinine &gt; 2.0 mg/dL OR 2 . Active , untreated SSc renal crisis time enrollment Active hepatitis liver biopsy evidence cirrhosis periportal fibrosis . Total bilirubin &gt; 2.5 x upper limit normal ( related Gilbert 's syndrome ) and/or Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 4 x upper limit normal Patients poorly control hypertension Patients whose life expectancy severely limited illness autoimmune disease DONOR : Identical twin patient Female donor pregnant ( positive BHCG ) breastfeed Infection human immunodeficiency virus ( HIV ) active viral hepatitis ( B C ) Known allergy GCSF Current serious systemic illness Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) Donors receive experimental therapy investigational agent Donors cancer treat basal cell carcinoma situ cervix ; Cancer treat curative intent &gt; 2 year previous review casebycase basis Protocol Chair Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Scleroderma , systemic sclerosis , allogeneic hematopoietic stem cell transplantation</keyword>
</DOC>